Literature DB >> 2242303

Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study.

R Bogdanović1, M Banićević, A Cvorić.   

Abstract

Testicular function of 17 males treated in childhood or adolescence for nephrotic syndrome (NS) with cyclophosphamide (CY) for a mean time of 240 days (mean total dosage of 16.4 g or 641 mg/kg body weight) was evaluated at a mean time of 11.8 years after treatment. Five were azoospermic, 1 oligospermic, and 11 normospermic. There was a significant inverse correlation of sperm density with CY dosage and duration of treatment. All patients had undergone normal pubertal development and had normal sexual characteristics. Both basal and gonadotropin-releasing hormone-stimulated follicle-stimulating hormone (FSH) and luteinizing hormone (LH) concentrations were significantly raised in oligo- and azoospermic patients. Raised basal and peak FSH and LH concentrations in normospermic patients with a sperm count of less than 40 x 10(6)/ml were in keeping with impairment of two testicular components. However, mean basal plasma testosterone levels and mean peak plasma testosterone responses to human chorionic gonadotropin (HCG) did not differ significantly between patients and controls. Although LH responses to gonadotropin-releasing hormone suggested compensated Leydig cell failure in patients with testicular tubular damage, secretory reserve capacity of these cells, estimated by a HCG stimulation test, was preserved. Further follow-up is required to ascertain whether in these patients Leydig cell failure will develop with time.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242303     DOI: 10.1007/bf00869818

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  18 in total

1.  Postpubertal evaluation of gonadal function following cyclophosphamide therapy before and during puberty.

Authors:  R D Lentz; J Bergstein; M W Steffes; D R Brown; K Prem; A F Michael; R L Vernier
Journal:  J Pediatr       Date:  1977-09       Impact factor: 4.406

2.  Gonadotropin response to luteinizing hormone-releasing hormone in men with germinal aplasia.

Authors:  R S Mecklenburg; R J Sherins
Journal:  J Clin Endocrinol Metab       Date:  1974-06       Impact factor: 5.958

3.  Cyclophosphamide and the pubertal testis.

Authors:  J Rapola; O Koskimies; N P Huttunen; P Floman; J Vilska; N Hallman
Journal:  Lancet       Date:  1973-01-13       Impact factor: 79.321

4.  Sterility and testicular atrophy related to cyclophosphamide therapy.

Authors:  K F Fairley; J U Barrie; W Johnson
Journal:  Lancet       Date:  1972-03-11       Impact factor: 79.321

5.  Testicular function in prepubertal and pubertal male patients treated with cyclophosphamide for nephrotic syndrome.

Authors:  J Penso; B Lippe; R Ehrlich; F G Smith
Journal:  J Pediatr       Date:  1974-06       Impact factor: 4.406

6.  Monotropic increase of serum FSH correlated with low sperm count in young men with idiopathic oligospermia and aspermia.

Authors:  S W Rosen; B D Weintraub
Journal:  J Clin Endocrinol Metab       Date:  1971-03       Impact factor: 5.958

7.  Physiology and pathology of the Leydig cell.

Authors:  M B Lipsett
Journal:  N Engl J Med       Date:  1980-09-18       Impact factor: 91.245

8.  Plasma gonadotropins and gonadal steroids in children treated with cyclophosphamide.

Authors:  A Parra; D Santos; C Cervantes; I Sojo; A Carranco; V Cortés-Gallegos
Journal:  J Pediatr       Date:  1978-01       Impact factor: 4.406

9.  Gonadal function in boys with steroid-responsive nephrotic syndrome treated with cyclophosphamide for short periods.

Authors:  R S Trompeter; P R Evans; T M Barratt
Journal:  Lancet       Date:  1981-05-30       Impact factor: 79.321

10.  Gonadotropin responses to luteinizing releasing factor in boys treated with cyclophosphamide for nephrotic syndrome.

Authors:  R T Kirkland; A M Bongiovanni; D Cornfield; J B McCormick; J S Parks; A Tenore
Journal:  J Pediatr       Date:  1976-12       Impact factor: 4.406

View more
  4 in total

1.  The long-term outcome of childhood nephrotic syndrome in Germany: a cross-sectional study.

Authors:  Malik Aydin; Ingo Franke; Lisa Kurylowicz; Rainer Ganschow; Michael Lentze; Mark Born; Rebekka Hagemann
Journal:  Clin Exp Nephrol       Date:  2019-02-05       Impact factor: 2.801

2.  Alternative treatment to corticosteroids in steroid sensitive idiopathic nephrotic syndrome.

Authors:  T J Neuhaus; J Fay; M J Dillon; R S Trompeter; T M Barratt
Journal:  Arch Dis Child       Date:  1994-12       Impact factor: 3.791

3.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.

Authors:  Kenji Ishikura; Shinsuke Matsumoto; Mayumi Sako; Kazushi Tsuruga; Koichi Nakanishi; Koichi Kamei; Hiroshi Saito; Shuichiro Fujinaga; Yuko Hamasaki; Hiroko Chikamoto; Yasufumi Ohtsuka; Yasuhiro Komatsu; Toshiyuki Ohta; Takuhito Nagai; Hiroshi Kaito; Shuji Kondo; Yohei Ikezumi; Seiji Tanaka; Yoshitsugu Kaku; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-02       Impact factor: 2.617

4.  The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review.

Authors:  L F Perez-Garcia; R J E M Dolhain; S Vorstenbosch; W Bramer; E van Puijenbroek; J M W Hazes; B Te Winkel
Journal:  Hum Reprod Update       Date:  2020-11-01       Impact factor: 15.610

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.